XtalPi forges AI drug discovery collaboration worth up to $250m with Lilly
The drug discovery partnership will make use of XtalPi’s integrated AI capabilities and robotics platform to design and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 May 23
The drug discovery partnership will make use of XtalPi’s integrated AI capabilities and robotics platform to design and…
31 May 23
The platform enables a research strategy that uses Kiyatec's capacity to correctly dissociate and characterise primary patient tissues…
30 May 23
The new data is generated from preclinical studies conducted in a laboratory at the Garvan Institute of Medical…
30 May 23
Maintenance of the license is now subject to the launch of the OATO Phase III before May 2024…
29 May 23
Inpefa is an oral inhibitor of sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1), administered as a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 May 23
Paxlovid is an oral SARS-CoV-2 main protease (Mpro) inhibitor therapy, containing 300mg nirmatrelvir and 100mg ritonavir at a…
26 May 23
The facility now offers storage, kitting, and distribution of advanced therapies for clinical trials, specifically focusing on ultra-low…
25 May 23
During pre-clinical pharmacological studies, BRY812 showed considerable antitumour activity in multiple tumour models
25 May 23
With an extensive pipeline focused on DDR and strategic partnerships with global pharmaceutical companies, Artios has chosen ANGLE…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 May 23
Post-merger, the combined firm, which is expected to operate as TuHURA Biosciences and trade on Nasdaq Capital Market,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates